DocWire News Editors

DocwireNews

<p>For patients undergoing cardiopulmonary bypass surgery, being administered intravenous steroids does not mitigate their risk of developing acute kidney injury, according to a <a href="http://www.cmaj.ca/content/191/9/E247">study</a> published in the <em>Canadian Medical Association Journal (CMAJ).</em><p>It is estimated that of the 4 million annual cardiopulmonary bypass surgeries performed worldwide, about 20% are complicated by the onset of acute kidney injury, defined as a rapid decline in kidney function. This adverse occurrence is associated with longer hospital stays, augmented health care costs, and death. In extreme cases, acute kidney disease patients may require the use of dialysis to sustain life. Because currently, an intervention that can be implemented to decrease the risk of acute kidney injury has proven evasive, researchers sought to test the efficacy of steroid therapy being utilized on patients undergoing a cardiopulmonary bypass.</p><h2><strong>Enlisting the Trial Subjects</strong></h2><p>The researchers for this international study recruited 7,286 patients from 79 centers across 18 countries (Canada, China, India, United States, Colombia, Australia, Italy, Iran, Czech Republic, Greece, Spain, Brazil, Austria, Belgium, Hong Kong, Argentina, Chile, and Ireland), and conducted a prespecified sub-study of a randomized controlled trial. They set eligibility criteria to include moderate-to-high risk of perioperative death on a score of six or greater based on the European System for Cardiac Operative Risk Evaluation. Patients were arbitrarily assigned (1:1) to receive either the intravenous steroid, methylprednisolone (250 mg at anesthetic induction and 250 mg at start of cardiopulmonary bypass), or a placebo. Caregivers, patients, data collectors and outcome analyzers were all appraised of the assigned intervention. The primary study outcome of interest was postoperative acute kidney injury, defined as an increase in the serum creatinine concentration of 0.3 mg/dL or greater, or 50% or greater in the 14-day period post-surgery, or the post-surgery use of a dialysis machine within 30 days.</p><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
<p lang="en" dir="ltr">Steroid use during cardiac bypass surgery did not reduce risk of severe kidney&nbsp;injury <a href="https://t.co/3zH0mkf1KF">https://t.co/3zH0mkf1KF</a></p>
<p>&mdash; TheBiotechTimes (@BiotechTimes) <a href="https://twitter.com/BiotechTimes/status/1102464828164239366?ref_src=twsrc%5Etfw">March 4, 2019</a></p>
</blockquote><p><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></p><h2><strong>Steroids Do Not Reduce Risk to Kidneys</strong></h2><p>The trial disclosed that acute kidney injury occurred in 40.6% (n=3,647) patients in the steroid group, compared to 39.2% (n=3,3639) patients in the placebo control (adjusted RR=1.04; 95% CI, 0.96 to 1.11). These results were consistently displayed across several definitions of acute kidney injury and in patients with chronic, preoperative kidney disease.</p><p>&ldquo;Given the broad range of countries and populations represented in the study, these findings further support a shift away from using steroids as an effective method of preventing the complications from inflammation during bypass surgery,&rdquo; says study author Dr. Amit Garg, a scientist at Lawson Health Research Institute and professor at Schulich School of Medicine &amp; Dentistry, Western University, London, Ontario, said in a <a href="https://www.eurekalert.org/pub_releases/2019-03/cmaj-sud022619.php">press release</a>. While providing a summation of their findings, they would continue by remarking, &ldquo;the lack of evidence of a protective effect of steroids combined with some adverse effects that prophylactic use of steroids during cardiopulmonary <a href="https://proddocwire.wpengine.com/docwire-pick/overlapping-surgeries-safe/">bypass surgery</a> is not warranted.&rdquo;</p><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
<p lang="en" dir="ltr">Steroid use during cardiac bypass <a href="https://twitter.com/hashtag/surgery?src=hash&amp;ref_src=twsrc%5Etfw">#surgery</a> did not reduce risk of severe <a href="https://twitter.com/hashtag/kidney?src=hash&amp;ref_src=twsrc%5Etfw">#kidney</a> injury <a href="https://twitter.com/CMAJ?ref_src=twsrc%5Etfw">@CMAJ</a> <a href="https://twitter.com/CMAJ?ref_src=twsrc%5Etfw">@CMAJ</a> <a href="https://t.co/93Y0PSu1yp">https://t.co/93Y0PSu1yp</a></p>
<p>&mdash; Medical Xpress (@physorg_health) <a href="https://twitter.com/physorg_health/status/1102486247308750848?ref_src=twsrc%5Etfw">March 4, 2019</a></p>
</blockquote><p><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></p><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
<p lang="en" dir="ltr">Steroid use during cardiac bypass surgery did not reduce risk of severe kidney injury <a href="https://t.co/UorWph5ss5">https://t.co/UorWph5ss5</a></p>
<p>&mdash; healthmedicinet (@healthmedicinet) <a href="https://twitter.com/healthmedicinet/status/1102508657592422400?ref_src=twsrc%5Etfw">March 4, 2019</a></p>
</blockquote><p><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></p><p>&nbsp;</p></p>


Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

The Use of Steroids is Ineffective at Preventing Kidney Injury During Cardiac Bypass Surgery

Cardiology

For patients undergoing cardiopulmonary bypass surgery, being administered intravenous steroids does not mitigate their risk of developing acute kidney injury, according to a ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe